Zoetis Inc.
ZTS Healthcare · Drug Manufacturers - Specialty & GenericDeep value.
Deep Value (Bullish) — Filing.fyi's reading derived from the latest 10-K and forensic scores.
The four readings.
What the filing actually says.
Zoetis’s latest 10-Q, filed May 7, 2026, presents a narrative that frequently directs the reader elsewhere for context. The Management’s Discussion and Analysis (MD&A) explicitly refers to the 2025 10-K for details on the operating environment, and highlights the use of non-GAAP financial measures—non-standard metrics often adjusted by management—for operational results and adjusted net income. This quarter’s revenue was $2,262 million, an increase from $2,198 million in the prior year period, suggesting continued top-line growth.
Forensic scores paint a picture of financial stability. Beneish’s 1999 eight-ratio earnings-manipulation detector registers at -2.4477, well below the -1.78 threshold that would suggest elevated manipulation risk. Altman’s Z″, a 1968 bankruptcy-distress index, stands at 4.49, firmly in the “safe” category, indicating minimal near-term solvency concerns. The Piotroski F-Score, a 2000 9-point fundamental strength scan, comes in at 6.0, suggesting a generally sound financial position, though not reaching the highest tier of fundamental strength.
The MD&A explicitly notes the Quarterly Variability of Financial Results, attributing it to factors such as tariffs, global macroeconomic conditions, competitive dynamics, and geopolitical tensions. This section, while brief, serves as a reminder that even established companies operate within a complex, unpredictable external environment. The company’s choice to direct readers to its 2025 Annual Report on Form 10-K for a full description of its operating environment means this 10-Q provides updates rather than a comprehensive standalone overview of these material factors.
This filing offers a snapshot of Zoetis’s financial health and reporting practices, indicating robust forensic scores and a structured approach to disclosures. It highlights management’s reliance on non-GAAP metrics and cross-referencing to prior annual reports for foundational context. However, the 10-Q does not, by itself, provide a complete basis for assessing the security’s intrinsic value or future market performance, which would require deeper analysis of sector trends, competitive positioning, and the long-term impact of the macroeconomic factors mentioned.
Filing timeline
- May 7, 202610-QQuarterly report (2026-03-31)Period: 2026-03-310Read →
- May 7, 20268-KMaterial event (2026-05-07)### Item 2.02 Results of Operations and Financial Condition On May 7, 2026, Zoetis Inc . (the Company) issued a press release reporting its financial results fo0Read →
- Apr 8, 2026DEF 14AProxy statement (2025-12-31)0Read →
- Feb 12, 202610-KAnnual report (2025-12-31)Period: 2025-12-310Read →
- Feb 12, 20268-KMaterial event (2026-02-12)### Item 2.02 Results of Operations and Financial Condition On February 12, 2026, Zoetis Inc . (the Company) issued a press release announcing its financial res0Read →
- Feb 5, 20268-KMaterial event (2026-02-05)No specific items found in 8-K.0Read →
If this case caught your eye
Financial Shenanigans
Schilit's framework for the seven shenanigan types is the standard reference for the kind of MD&A pattern-matching this site does.
View on Amazon →The Interpretation of Financial Statements
The original — and still the clearest — explanation of why working-capital trends matter more than headline earnings.
View on Amazon →Quality of Earnings
Out of print, expensive, worth it. The chapter on receivables-vs-revenue divergence applies almost word-for-word to most distressed filings.
View on Amazon →